We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cardiovascular risk
MedXY News
EnglishTag

cardiovascular risk

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Prior Myocardial Infarction and Cognitive Decline: Insights from the REGARDS Cohort
Cardiologycardiovascular riskcognitive decline

Prior Myocardial Infarction and Cognitive Decline: Insights from the REGARDS Cohort

By MedXY|May 16, 2026

In the REGARDS cohort, prior myocardial infarction, including silent MI, was linked to faster long-term cognitive decline, suggesting heart attack history may help identify people at risk for future cognitive impairment.

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation
Cardiologyatrial fibrillation
biomarkers

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation

By MedXY|May 18, 2026

This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial
Cardiologycardiovascular riskHypercholesterolemia

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

By MedXY|May 15, 2026

Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD
Cardiologycardiovascular riskCOPD

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

By MedXY|May 11, 2026

COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su

Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE Trial
Cardiologycardiovascular riskheart failure

Elevated Heart Failure Risk in People With HIV: Insights from the REPRIEVE Trial

By MedXY|Apr 30, 2026

The REPRIEVE trial reveals higher heart failure incidence in people with HIV, particularly among women, Black participants in high-income regions, and those with hypertension or obesity. Traditional risk factors, not HIV-specific markers, w

Prolonged TSH Suppression in Postmenopausal Thyroid Cancer Patients Linked to Worse Cardiovascular and Quality-of-Life Outcomes
Cardiologycardiovascular riskdifferentiated thyroid cancer

Prolonged TSH Suppression in Postmenopausal Thyroid Cancer Patients Linked to Worse Cardiovascular and Quality-of-Life Outcomes

By MedXY|Apr 30, 2026

Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes
Clinical Updatescardiovascular riskGLP-1 RA

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes

By MedXY|Apr 27, 2026

A large-scale cohort study demonstrates that GLP-1 RAs significantly reduce macrovascular and microvascular complications, including proliferative retinopathy and retinal vein occlusion, in patients with pre-existing diabetic retinopathy.

44% of Women with HDP Develop Chronic Hypertension Within 10 Years: Missed Opportunities in Postpartum Care
Cardiologycardiovascular riskchronic hypertension

44% of Women with HDP Develop Chronic Hypertension Within 10 Years: Missed Opportunities in Postpartum Care

By MedXY|Apr 23, 2026

A French cohort study reveals 44% of women receiving postpartum antihypertensives after HDP develop chronic hypertension within 10 years, signaling urgent gaps in long-term cardiovascular risk monitoring.

Even ‘Elevated’ Blood Pressure Raises Dementia Risk: Insights from 2.8 Million Adults Over 8 Years
Cardiologyblood pressurecardiovascular risk

Even ‘Elevated’ Blood Pressure Raises Dementia Risk: Insights from 2.8 Million Adults Over 8 Years

By MedXY|Apr 15, 2026

A landmark South Korean study of 2.8 million adults reveals that both elevated blood pressure and hypertension significantly increase dementia risk, particularly vascular dementia, with stronger effects observed in midlife adults and women.

AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial
Cardiologyartificial intelligenceatrial fibrillation

AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial

By MedXY|Apr 15, 2026

A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most fro

Longer Wait, Higher Risk? How Timing of Hypertensive Disorder Diagnosis Shapes Women’s Cardiovascular Future
Cardiologycardiovascular riskexpectant management

Longer Wait, Higher Risk? How Timing of Hypertensive Disorder Diagnosis Shapes Women’s Cardiovascular Future

By MedXY|Apr 14, 2026

New research reveals that longer latency between hypertensive disorder of pregnancy diagnosis and delivery correlates with subtle inflammatory and lipid changes in young mothers, suggesting subclinical cardiovascular risk elevation years af

Why Exercise Blood Pressure Alone May Miss Cardiovascular Risk—and What Combining It With Fitness Reveals
Cardiologyaerobic fitnesscardiovascular risk

Why Exercise Blood Pressure Alone May Miss Cardiovascular Risk—and What Combining It With Fitness Reveals

By MedXY|Apr 13, 2026

The EXERTION study of 12,743 individuals demonstrates that exercise systolic blood pressure relative to aerobic fitness (SBP/METPeak) is a powerful predictor of cardiovascular events, whereas exercise BP alone provides no prognostic value.

Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence
CardiologyBP Loweringcardiovascular risk

Efficacy of Blood Pressure-Lowering Pharmacotherapy in Isolated Diastolic Hypertension: A Systematic Synthesis of Evidence

By MedXY|Apr 13, 2026

This review synthesizes recent evidence, including a landmark 2026 meta-analysis, showing that blood pressure-lowering therapy provides similar cardiovascular benefits in patients with isolated diastolic hypertension compared to those with

Redefining Gout Management: Cardiovascular Risk Reduction via Treat-to-Target Urate-Lowering Therapy
Cardiologycardiovascular riskgout

Redefining Gout Management: Cardiovascular Risk Reduction via Treat-to-Target Urate-Lowering Therapy

By MedXY|Mar 28, 2026

Achieving serum urate targets <6 mg/dL (or <5 mg/dL) through Treat-to-Target (T2T) protocols significantly reduces major adverse cardiovascular events in gout patients, particularly those at high baseline risk.

Beyond Calcium: Postoperative Hypoparathyroidism Linked to Long-term Renal and Cardiovascular Risks in Thyroid Cancer Survivors
Diabetes & Endocrinologycardiovascular riskhypoparathyroidism

Beyond Calcium: Postoperative Hypoparathyroidism Linked to Long-term Renal and Cardiovascular Risks in Thyroid Cancer Survivors

By MedXY|Mar 22, 2026

A nationwide cohort study reveals that permanent postoperative hypoparathyroidism significantly increases the risk of renal insufficiency, nephrolithiasis, and major adverse cardiac events in thyroid cancer patients, highlighting the need f

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference
Cardiologybiomarkerscardiovascular risk

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

By MedXY|Mar 18, 2026

This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.

One-Hour Plasma Glucose: A Vital Predictor of Cardiometabolic Risk in Women with PCOS
Diabetes & Endocrinologycardiovascular riskGlucose Testing

One-Hour Plasma Glucose: A Vital Predictor of Cardiometabolic Risk in Women with PCOS

By MedXY|Mar 15, 2026

A retrospective study highlights how 1-hour plasma glucose levels can identify early cardiometabolic risks in women with PCOS who appear to have normal blood sugar levels.

Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality
Cardiologycardiovascular riskcoronary artery disease

Chronic Inflammation via suPAR: The Missing Link Between Diabetes and Cardiovascular Mortality

By MedXY|Mar 14, 2026

A landmark study in Diabetes Care reveals that soluble urokinase plasminogen activator receptor (suPAR) mediates over half of the increased risk for adverse cardiovascular outcomes in patients with diabetes and coronary artery disease, surp

Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment
Cardiologycardiovascular riskheart failure

Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment

By MedXY|Mar 11, 2026

This article details the SCORE2-HF risk model, a newly validated tool designed to estimate 10-year and 30-year heart failure risks in asymptomatic individuals, enabling earlier intervention and personalized cardiovascular care across divers

Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes
Cardiologycardiovascular risktestosterone

Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes

By MedXY|Mar 9, 2026

A longitudinal analysis of the Look AHEAD trial demonstrates that baseline testosterone and weight loss-induced changes in SHBG significantly modulate cardiovascular risk in men with type 2 diabetes, highlighting the critical role of hormon

Prev
3 / 6
123456
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure